Development of a one-step RT-ddPCR method to determine the expression and potency of AAV vectors.

AAV gene therapy assay development one-step RT-ddPCR potency assay vector expression

Journal

Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857

Informations de publication

Date de publication:
10 Dec 2021
Historique:
received: 26 01 2021
accepted: 07 05 2021
entrez: 30 9 2021
pubmed: 1 10 2021
medline: 1 10 2021
Statut: epublish

Résumé

Robust assays to quantify adeno-associated virus (AAV) vector expression and potency are essential for gene therapy development. These assays inform the efficacy, safety, and pharmacodynamic profiles of AAV development candidates. Additionally, for gene downregulation strategies such as RNAi, knockdown of endogenous genes reflects the mechanism of action of such development candidates. Therefore, a method to quantify target mRNA repression is necessary for measuring vector potency both

Identifiants

pubmed: 34589555
doi: 10.1016/j.omtm.2021.05.003
pii: S2329-0501(21)00087-5
pmc: PMC8449018
doi:

Types de publication

Journal Article

Langues

eng

Pagination

68-77

Informations de copyright

© 2021 The Author(s).

Déclaration de conflit d'intérêts

All authors were employees at Biogen at the time of the studies. The authors declare no competing interests.

Références

Sci Rep. 2020 Oct 30;10(1):18764
pubmed: 33127953
Methods Mol Biol. 2019;1950:51-83
pubmed: 30783968
Hum Gene Ther Methods. 2014 Apr;25(2):115-25
pubmed: 24328707
Hum Gene Ther. 2010 Oct;21(10):1273-85
pubmed: 20486768
Clin Chem. 2013 Jun;59(6):892-902
pubmed: 23570709
J Virol. 2009 Mar;83(6):2632-44
pubmed: 19109385
Neuron. 2019 Mar 6;101(5):839-862
pubmed: 30844402
Hum Gene Ther. 2021 May 6;:
pubmed: 33560161
Sci Rep. 2020 Nov 2;10(1):18878
pubmed: 33139839
Mol Ther Methods Clin Dev. 2020 Sep 01;19:89-98
pubmed: 33024793
Nat Rev Drug Discov. 2019 May;18(5):358-378
pubmed: 30710128
Gene Ther. 2012 Jun;19(6):649-58
pubmed: 22357511
J Virol Methods. 2021 Feb;288:114010
pubmed: 33152410
Front Microbiol. 2019 Jul 17;10:1570
pubmed: 31379763
PLoS One. 2013;8(4):e55943
pubmed: 23573183
Hum Gene Ther Methods. 2019 Aug;30(4):127-136
pubmed: 31140327
Anal Bioanal Chem. 2014 Jan;406(3):661-7
pubmed: 24276251
Clin Cancer Res. 2021 Jan 1;27(1):169-178
pubmed: 33051308
J Clin Microbiol. 2013 Feb;51(2):540-6
pubmed: 23224089

Auteurs

Pete Clarner (P)

Gene Therapy Accelerator Unit, Biotherapeutic and Medicinal Sciences, Biogen, 225 Binney Street, Cambridge, MA 02142, USA.

Shukkwan K Lau (SK)

Neuromuscular and Muscle Disorders Research Unit, Research, Biogen, 225 Binney Street, Cambridge, MA 02142, USA.

Twinkle Chowdhury (T)

Neuromuscular and Muscle Disorders Research Unit, Research, Biogen, 225 Binney Street, Cambridge, MA 02142, USA.

Edward Guilmette (E)

Gene Therapy Accelerator Unit, Biotherapeutic and Medicinal Sciences, Biogen, 225 Binney Street, Cambridge, MA 02142, USA.

Patrick Trapa (P)

Drug Metabolism and Pharmacokinetics, Biotherapeutic and Medicinal Sciences, Biogen, 225 Binney Street, Cambridge, MA 02142, USA.

Shih-Ching Lo (SC)

Neuromuscular and Muscle Disorders Research Unit, Research, Biogen, 225 Binney Street, Cambridge, MA 02142, USA.

Shen Shen (S)

Gene Therapy Accelerator Unit, Biotherapeutic and Medicinal Sciences, Biogen, 225 Binney Street, Cambridge, MA 02142, USA.

Classifications MeSH